Boston Scientific has enjoyed success in the cardiac device space, but it continues to look to gain market share elsewhere, ...

Boston Scientific Corporation BSX is scheduled to report second-quarter 2024 results on Jul 24, before the opening bell. In the last reported quarter, the company’s earnings per share of 56 cents ...

BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition ...

17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...

More special care is needed when using the Watchman access systems used to deliver transcatheter left atrial appendage (LAA) closure devices due to a risk for air embolisms, according to an FDA alert.

The U.S. FDA expanded the approval for use of Boston Scientific Corp.’s Watchman Flx and Watchman Flx Pro left atrial appendage closure (LAAC) devices to include post-ablation patients, bringing good ...

Boston Scientific’s BSX Cardiovascular segment operates in a $50 billion market, projected to grow nearly 9% over the 2026-2028 long-range plan (LRP). Management expects the business to outpace ...